GET DAILY SIGNALSWhy Is Iovance Biotherapeutics (IOVA) Stock Down -13.18% Today?
Key Takeaways
- Shares of IOVA are down 13.18% to about $8.30 in Friday trading, extending the prior session's steep sell-off.
- The slide is a continuation of the market's negative reaction to updated Phase 2 lung cancer data for lifileucel (Amtagvi), which showed a response rate that was essentially flat versus earlier results.
- A secondary driver is an analyst price-target reduction, reflecting reduced conviction in the lung cancer expansion opportunity.
- The move reflects a repricing of elevated expectations after the stock had rallied sharply in 2026.
- Traders are watching the company's third-quarter earnings report and the planned start of a biomarker-enriched trial cohort.
- For more detail on valuation, see Price Targets, upcoming Earnings, and the company's Forecast.
- Explore Trending AI Robots to see which automated strategies are navigating today's market conditions.
Opening Summary
Iovance Biotherapeutics (IOVA), a commercial-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) cell therapies for cancer, is extending its sharp decline in Friday's session. The stock is trading around $8.30, down approximately 13.18% from the prior close of $9.56. The move follows a roughly 35% plunge on Thursday, when the company released updated clinical data that failed to satisfy investor expectations for its lead therapy's expansion into lung cancer. The sell-off is being driven by concerns about the durability of responses and the narrow patient population in which the treatment demonstrated its strongest efficacy.
Lung Cancer Data Disappoints the Market
The primary catalyst is the company's updated Phase 2 IOV-LUN-202 trial results for lifileucel, marketed as Amtagvi for advanced melanoma, in patients with previously treated non-squamous metastatic non-small cell lung cancer (mNSCLC). Across 69 patients, the treatment produced a 24.6% objective response rate (ORR) — essentially unchanged from the 25.6% rate previously reported among 39 patients.
Investors had positioned for a more convincing readout after a powerful run-up in the shares. Instead, the release offered limited new information on how long responses lasted, with durability and safety addressed in a single statement that they remained "consistent with previous reports." The market's concern centers on the fact that responses were heavily concentrated in a specific subset: patients without KRAS and HER2 mutations who also had a history of smoking. That biomarker-enriched group, representing roughly a third of the trial population, showed a 59.1% ORR, while the KRAS-mutant subgroup responded at only 11.4%.
Management framed this as a "precision TIL" opportunity and announced a new biomarker-selected cohort, dubbed POSITILITY, expected to begin enrollment in November 2026, alongside plans for a supplemental Biologics License Application in 2027. However, the concentration of benefit in a narrower population has tempered the market's view of the addressable lung cancer opportunity.
Analyst Reactions and a Repricing of Expectations
The decline is also being compounded by early analyst responses. At least one firm lowered its price target on IOVA, trimming its target from $11 to $9 while maintaining a neutral stance. Other analysts reiterated more constructive views, pointing to the strong biomarker-selected subgroup and the commercial momentum of Amtagvi in melanoma. The divergence in analyst opinion underscores that the lung cancer readout is being interpreted less as a clinical failure and more as a recalibration of how broadly the therapy may ultimately be used.
Critically, the sell-off reflects the lofty expectations already embedded in the share price. IOVA had surged by more than 250% year-to-date ahead of the data, leaving little room for a readout that merely matched prior results rather than exceeding them. The stock's decline is therefore as much a valuation reset as it is a fundamental disappointment.
Market Context and Trading Activity
Trading volume has been exceptionally heavy. Thursday's session saw more than 41 million shares change hands, roughly 2.5 times the average volume, indicating broad-based distribution rather than isolated selling. Friday's continued weakness suggests that selling pressure is persisting as investors digest the clinical data and reposition ahead of the company's upcoming earnings report.
The move has diverged from the broader biotech sector, which has traded relatively steady during the period. This confirms that the decline is driven by company-specific clinical news rather than a sector-wide or macro-driven pullback. From a technical standpoint, the stock has broken decisively below its 50-day moving average and slid back into single-digit territory after a multi-month rally, reinforcing a bearish near-term setup.
What Comes Next for IOVA
The next major catalyst is the company's third-quarter 2026 earnings report, scheduled for November 5. Investors will focus on Amtagvi revenue growth, cash burn, and any updated guidance, particularly after management raised its full-year 2026 revenue outlook in September to a range of $410 million to $420 million.
Beyond earnings, attention will turn to the POSITILITY cohort's enrollment and the company's ability to demonstrate more durable responses in a prospectively selected patient population. The planned 2027 regulatory submission for the lung cancer indication remains a longer-term swing factor. Risks include continued cash outflows, reliance on a single commercial product, and the uncertainty inherent in translating biomarker-enriched results into a broader approved label.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that scan thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to evaluate automated approaches that adapt to shifting market dynamics. Explore the page to see which AI-driven strategies are currently demonstrating strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IOVA's RSI Oscillator is sitting in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 202 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
IOVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 137 of 164 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IOVA moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.313) is normal, around the industry mean (3.162). P/E Ratio (-12.290) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biotechnological products for the treatment of cancer
Industry Biotechnology
Advertisement